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The causes of autoimmune responses leading to human kidney pathology remain unknown.
However, environmental agents such as microorganisms and/or xenobiotics are good candidates
for that role. Metals, either present in the environment or administered for therapeutic reasons, are
prototypical xenobiotics that cause decreases or enhancements of immune responses. In particular,
exposure to gold and mercury may result in autoimmune responses to various self-antigens as well
as autoimmune disease of the kidney and other tissues. Gold compounds, currently used in the
treatment of patients with progressive polyarticular rheumatoid arthritis, can cause a nephrotic
syndrome. Similarly, an immune-mediated membranous nephropathy frequently occurred when
drugs containing mercury were commonly used. Recent epidemiologic studies have shown that
occupational exposure to mercury does not usually result in autoimmunity. However, mercury
induces antinuclear antibodies, sclerodermalike disease, lichen planus, or membranous nephropathy
in some individuals. Laboratory investigations have confirmed that the administration of gold or
mercury to experimental animals leads to autoimmune disease quite similar to that observed in
human subjects exposed to these metals. In addition, studies of inbred mice and rats have revealed
that a few strains are susceptible to the autoimmune effects of gold and mercury, whereas the
majority of inbred strains are resistant. These findings have emphasized the importance of genetic
(immunogenetic and pharmacogenetic) factors in the induction of metal-associated autoimmunity.
In vitroand in vivo research of autoimmune disease caused by mercury and gold has already yielded
valuable information and answered a number of important questions. At the same time it has raised
new issues about possible immunostimulatory or immunosuppressive mechanisms of xenobiotic
activity. Thus it is evident that investigations of metal-induced renal autoimmunity have the potential
to produce new knowledge with relevance to autoimmune disease caused by xenobiotics in
general as well as to idiopathic autoimmunity. Key words: autoimmunity, gold, kidney, mercury,
metals. - Environ Health Perspect 107(suppl 5):753-765 (1999).
http.//ehpnet1.niehs.nih.gov/docs/1999/suppl-5/753-765bigazzi/abstract.html
Clinical manifestations, pathology, and
pathogenesis ofkidney disease are complex
and diverse. They are easier to understand
when divided into separate clinicopathologic
entities on the basis of the renal structures
(glomerulus, tubules, interstitium, and
blood vessels) that are the primary targets of
injury (1). Great progress in our knowledge
of kidney disease has also been achieved
through clinical and experimental studies
that have revealed some ofthe immunologic
mechanisms involved in renal diseases. For
the benefit of readers with little knowledge
ofkidney pathology, I will first summarize
in a schematic fashion the major immune-
mediated kidney disorders (Table 1).
Kidney disease can be the result of
glomerular and/or tubulointerstitial injury
due to one or more of the following basic
tissue reactions.
Inflammation (influx ofleukocytes) in
the glomerulus. Inflammation (influx of
leukocytes) in the glomerulus causes a
nephritic (glomerulonephritic) syndrome with
increased permeability to red cells (hematuria)
as well as decreased glomerular filtration rate
(leading to increased blood urea nitrogen and
creatinine). The glomerulus is also more per-
meable to proteins, which results in mild to
severe proteinuria. There are various types of
glomerulonephritis. Acute endocapillary
glomerulonephritis is characterized by abrupt
onset ofrenal dysfunction with hematuria of
glomerular origin. Glomerular hypercellular-
ity, composed ofinflammatory cells and pro-
liferating mesangial and endothelial cells, is
the most important pathologic lesion (2). The
prototype ofthis condition is poststreptococ-
cal glomerulonephritis, but it has also been
observed in other infectious diseases and in
some patients with systemic lupus erythe-
matosus (SLE) (3). Crescentic glomeru-
lonephritis, also called rapidly progressive
glomerulonephritis, causes hematuria and a
rapid, progressive dedine in glomerular filtra-
tion rate (4,5). Its pathology is characterized
by glomerular inflammation, necrosis, and
proliferating glomerular epithelial cells with
formation ofcrescents occupying Bowman's
spaces (6,7). Its immunopathology is variable.
Linear binding ofIgG and C3 to glomerular
capillary loops is observed in patients with
Goodpasture's syndrome. Granular deposits
ofIgG and C3 in the glomeruli are noted in
patients with SLE. Pauci-immune crescentic
glomerulonephritis with a negative immuno-
fluorescence (IF) pattern (i.e., without
demonstrable renal binding of immuno-
globulins and complement) is observed in
patients with vasculitides and is usually
associated with circulating antineutrophil
cytoplasmic autoantibodies (8).
Thickening ofglomerular basement
membranes. Thickening ofglomerular base-
ment membranes (GBMs), another basic tis-
sue reaction affecting glomerular filtration,
causes the nephrotic syndrome characterized
by increased glomerular permeability with
massive leakage ofalbumin (proteinuria, more
than 3.5 g/day), hypoalbuminemia, and
edema (9,10). It occurs in a pure nephrotic
form (bland urine sediment, i.e., onlyalbumin
and no red cells) in patients with minimal-
change disease or membranous nephropathy.
The histopathology ofminimal change disease
shows a paucity ofglomerular changes by light
microscopy (11-13). Similarly, there are no
detectable immune deposits by immunofluo-
rescence. However, electron microscopy
reveals effacement ofpodocyte foot processes,
swelling ofendothelial cells, and occasionally
small subendothelial deposits. The pathogene-
sis of this condition is uncertain, but
immunologic mechanisms may be involved
(11,14). Membranous nephropathy, also
called membranous glomerulonephropathy or
membranous glomerulonephritis, is character-
ized by thickening ofglomerular capillary
walls and absence of inflammatory cells.
Granular deposits of immunoglobulins and
subepithelial electron-opaque deposits are pre-
sent in the GBM (15-17). In addition, thin
argyrophilic projections (spikes) arise from the
lamina densa of the GBM. A mixed
nephrotic/nephritic form of the nephrotic
syndrome (with active urine sediment, i.e.,
hematuria and proteinuria) occurs in patients
with mesangiocapillary glomerulonephritis,
also called membranoproliferative glomeru-
lonephritis, (18-21). Various degrees of
increases in mesangial cells and matrix, as well
as thickening ofthe capillarywalls, distinguish
several histopathologic types of mesangio-
capillaryglomerulonephritis.
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Table 1. Summary of major immunologically mediated kidney diseases.
Majorclinical signs of renal disease Kidney histopathology Kidney immunohistopathology
Poststreptococcal
glomerulonephritis
Crescentic glomerulo-
nephritis
Minimal change
disease
Membranous glomeru-
lopathy
Membranoproliferative
(mesangiocapillary)
glomerulonephritis
lupus nephritis
Acute interstitial nephritis
Chronic tubulointerstitial
nephropathy
Nephronal hematuria, mild to severe
proteinuria, oliguria, and eventual
renal failure overweeks to months
Nephronal hematuria, variable proteinuria,
renal failure overweeks to months
Edema, proteinuria, hypoalbuminemia
Heavy proteinuria (>0.5 g protein/24 hr),
hypoalbuminemia, edema
Proteinuria and hematuria
Proteinuria, hematuria
Sudden decrease in renal function,
fever, hematuria
Polyuria, nocturia, mild proteinuria
Acute inflammation (PMN), proliferation
of mesangial and epithelial cells
Acute inflammation (PMN), necrosis,
proliferation of mesangial and
epithelial cells, crescents in
> 50% of glomeruli
Effacement offoot processes of
epithelial cells
Thickening of GBM, no inflammation
Proliferation of mesangial and epithelial
cells, thickening of GBM, inflammation
(PMN and monocytes)
Normal glomeruli (class 1, <5%); pure
mesangial alterations (class 11, 15%);
focal proliferative glomerulonephritis
(class I11, 20%); diffuse proliferative
glomerulonephritis (class IV, 50%); mem-
branous glomerulonephritis (class V, 15%)
Interstitial edema, inflammation, tubular
necrosis
Chronic inflammation, interstitial fibrosis,
tubularatrophy
Granular lgG and C3 (subepithelial) deposits in GBM
Linear lgG deposits in GBM and TBM (anti-GBM
antibody-mediated type)
Granular lgG and C3 (subepithelial) deposits in GBM
(immune complex-mediated type)
No immune deposits (pauci-immune and ANCA-
associated type)
No immune deposits or small subendothelial
deposits
Granular lgG and C3 (subepithelial) deposits in GBM
Granular C3 and lgG (subendothelial, intramem-
branous, subepithelial) deposits in GBM
Mesangial immune deposits (class 11, Ill, IV, V)
Subendothelial immune deposits (class Ill, IV)
Subepithelial immune deposits (class V, Ill, IV)
Infiltrates with T cells and macrophages. Tubular
immune deposits in some cases
Infiltrates with T cells and macrophages
Abbreviations: ANCA, anti-neutrophil cytoplasmic autoantibodies; GBM, glomerular basement membrane; PMN, polymorphonuclear leukocytes; TBM, tubularbasement membrane.
Morphologic andelinicalmanifestations.
Many of these morphologic and clinical
manifestations, defined by the term lupus
nephritis, are observed in patients with
SLE (22-24). The latest World Health
Organization dassification of renal pathology
in SLE encompasses several types of renal
glomerular changes. Kidney glomeruli may
appear normal by light microscopy but show
small mesangial immune deposits and are
identified as class I. More severe pathology
comprises pure mesangial alterations (class
II), focal proliferative glomerulonephritis
(class III), diffuse proliferative glomeru-
lonephritis (dass IV), membranous glomeru-
lonephritis (class V), and advanced sclerosing
glomerulonephritis (class VI). Immune renal
deposits containing IgG, IgM and C3 are
detected in most patients with SLE, either in
the mesangium (especially in class II kidneys)
or at the subendothelial (classes III and IV) or
subepithelial level (especially in class V).
Tubulointerstitial syndromes. Inflam-
mation oftubules and interstitium with rela-
tive sparing of glomeruli causes acute or
chronic tubulointerstitial syndromes with
defects in tubular function (25,26). Acute
tubulointerstitial nephritis is characterized by
a sudden clinical onset, decrease in renal
function, fever, and hematuria. There is renal
interstitial edema, leukocytic infiltration, and
focal tubular necrosis (27). Chronic tubu-
lointerstitial nephritis is distinguished by
polyuria, nocturia, and mild proteinuria. Its
histopathology shows mononuclear cell
infiltration and fibrosis ofthe renal intersti-
tium as well as tubular atrophy. Both acute
and chronic tubulointerstitial nephritis are
caused by reactions to certain drugs, infec-
tions, and/or immune mechanisms (25).
Either form can be observed in kidneys of
some patients with SLE, where interstitial
inflammation may be predominant over the
glomerular lesions.
Immunologically mediated injury is a
common pathogenesis of the kidney dis-
orders summarized above (28-32). Renal
damage can be caused by deposition of pre-
formed immune complexes present in the
circulation. It can also be due to in situ
immune complex formation. This may occur
when antibodies bind to exogenous or
endogenous antigens planted within kidney
structures. Alternatively, antibodies may
react with intrinsic components ofglomeruli
and/or tubules. Finally, kidney lesions can
result from the activity and products ofpoly-
morphonuclear leukocytes (PMNs), effector
T cells, and macrophages. In many cases the
damaging immune responses are of an
autoimmune nature, as they are directed
against self-antigens ofthe kidney or other
host tissues (33-36). The causes initiating
autoimmune responses leading to human
kidney pathology remain unknown.
However, environmental agents such as
microorganisms and/or xenobiotics are good
candidates for that role. The concept that
bacteria and viruses may cause autoimmune
disease has been accepted for a long time,
even though the evidence available is rela-
tively sparse (37,38). Less recognized is the
possible role of xenobiotics as inducers of
autoimmunity (39).
Xenobiotics are foreign substances of
synthetic, natural, or biologic origin that can
affect the immune system and cause either
immunosuppression or allergic and autoim-
mune responses (39-50). Metals, either pre-
sent in the environment or administered for
therapeutic reasons, are prototypical xeno-
biotics and can cause decreases or enhance-
ments of immune responses. However, their
influence on the immune system does not
necessarily imply that they can induce
autoimmunity, as shown by a group ofmetals
comprising arsenic, beryllium, iron, nickel,
and vanadium that have recognized immuno-
toxic activity. To date, there are no well-doc-
umented reports that these metals cause
autoimmune responses or autoimmune dis-
ease (Table 2). A second group ofimmuno-
toxic metals, induding cadmium, chromium,
copper, lead, platinum, and zinc, has only
occasionally been associated with autoimmu-
nity (Table 2). However, exposure to silver,
lithium, gold, and mercury often results in
autoimmune responses. Silver has immuno-
toxic effects on human lymphocytes and neu-
trophils (72), but to date we have found no
reports ofkidney autoimmunity in humans.
The lack of human autoimmune disease
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Table 2. Metals associated with autoimmune responses and autoimmune disease.
Metala Autoimmune responses(human and/or animal) Human autoimmune disease Animal autoimmune disease References
Arsenic, beryllium, None reported to date None reported to date None reported to date (51-55)
iron, nickel,
vanadium
Cadmium Autoantibodies to laminin 1 (?) None reported to date None reported to date (56-59)
Chromium ANA(?) SLE-like syndrome, pemphigus (?) None reported to date (60-62)
Copper Autoantibodies to red cells (?) None reported to date None reported to date (60, 63)
Lead IgM autoantibodies to neuroproteins (NFl60 None reported to date None reported to date (64,65)
and MBP)(?), lgG autoantibodies to
neuroproteins (NF-68 and GFAP) (?)
Platinum ANA (?) None reported to date None reported to date (66,67)
Zinc None reported to date Multiple sclerosis cluster)?) None reported to date (55,68-71)
Silver Autoantibodies to fibrillarin None reported to date None reported to date (72-75)
Lithium Autoantibodies to thyroglobulin, autoantibodies Autoimmune thyroid disease, SLE-like Autoimmune thyroid disease (76-79)
to thyroid peroxidase, ANA, autoantibodies to syndrome
gastric parietal cells
Gold ANA, anti-Ro autoantibodies, antiplatelet Autoimmune kidney disease, autoimmune Autoimmune kidney disease (80-86)
autoantibodies, autoantibodies to laminin 1 thrombocytopenia, SLE-like syndrome,
pemphigus
Mercury Autoantibodies to fibrillarin, autoantibodies Autoimmune kidney disease, lichen planus, Autoimmune kidney disease, (44,58,86-93)
to laminin 1, autoantibodies to DNA and sclerodermalike disease GvH-like disease, arthritis,
otherANA, autoantibodies to thyroglobulin vasculitis
Abbreviations:?, isolated reports to be confirmed byadditional studies; ANA, antinuclear antibodies; GvH, graft-versus-host; SLE, systemic lupus erythematosus. ¶Listed in order of autoimmune potential.
resulting from exposure to silver may be
explained by studies ofmice treated with this
metal that develop autoantibodies to nucleo-
lar antigens but for reasons still unknown
have no significant renal immune deposits or
apparent renal pathology (73-75). Lithium
facilitates preexisting autoimmune thyroid
disease, but its association with the develop-
ment ofa nephrotic syndrome is still uncer-
tain (77,94,95). Finally, gold and mercury
can actually induce autoimmune disease of
the kidneyand other tissues (Table 2).
Because oftheir demonstrated pathogenetic
potential, in the present review I will focus on
the autoimmune effects ofgold and mercury.
Autoimmune disease caused by gold was first
described in the 1950s and 1960s but lately has
notattracted much research attention. Thus, we
lack up-to-date knowledge ofthe mechanisms
involved in the loss oftolerance to self-antigens
following the therapeutic administration ofgold
compounds. Conversely, mercury-induced
autoimmunity has been amply investigated in
both humans and experimental aniimals. Recent
studies using genetically modified mice have
provided interesting data on the in Vtivo interac-
tions between mercury and immune cells
responsible for cytokine production. This infor-
mation mayapply to autoimmunity induced by
xenobiotics in general and perhaps to idiopathic
autoimmunity(44).
Gold-induced Renal
Autoimmunity
Gold has been recently described as
"possibly the most ancient and ... one ofthe
most modern agents in all of medicine's
pharmacopoeia" (96). It has also become one
of the most common allergens and in some
countries is second only to nickel in the etiol-
ogy of cutaneous hypersensitivity reactions
(97). In spite ofthese immunotoxic effects,
environmental or occupational exposure to
gold does not seem to cause major renal
pathology. Workers employed in gold mining
and refining as well as goldsmiths and neigh-
bors ofgold shops in the Amazon are more
likely to show evidence ofmercury, not gold,
contamination (98). However, a recent
report of rapidly progressive interstitial lung
fibrosis (Hamman-Rich syndrome) in a gold-
smith has raised the possibility that occupa-
tional exposure to this metal may occasionally
have pathologic consequences (99). This is
suggested by the occurrence of interstitial
lung fibrosis, possibly with an autoimmune
pathogenesis, as a rare complication oftreat-
mentwith gold compounds (100).
The medical literature contains numerous
reports ofhuman disease from therapy with
gold salts, self-administration offolk remedies
containing gold, or the ingestion ofliquor
containing this metal (101-105). Since the
1920s, gold compounds have been employed
in the western world for the treatment of
rheumatoid arthritis (RA). In North America,
gold sodium thiomalate and gold sodium
thioglucose are used primarily in patients
with progressive polyarticular RA (106).
Gold therapy is also recommended for
selected patients with juvenile RA, psoriatic
arthritis, or ankylosing spondilitis. The mech-
anisms underlying the therapeutic effects of
gold compounds are still rather uncertain, but
recently it has been suggested that they
inhibit the proinflammatory transcription
factorsAP-1 and NF-KB (107-109).
Both autoimmune responses and disease
are well-documented consequences of gold
treatment, as shown by numerous reports
published in the period between 1960 and
1970 (Table 2). Unfortunately, little atten-
tion is currently given in the United States to
gold-induced autoimmunity, and only a few
European investigators have continued to
study the pathogenesis of these adverse
effects (48,84,110).
Effects ofGoldonCells
oftheImmuneSystem
The literature on the immunotoxic effects of
gold compounds is rather sparse. Early studies
observed a gold-induced modulation ofmeta-
bolic events in leukocytes (PMNs, B cells)
stimulated by phorbol esters (111,112). Gold-
containing compounds can inhibit mitogen-
induced T cell activation and cause a marked
decrease in interleukin (IL)-2 release by pep-
tide-specific murine CD4+T-cell clones (113).
Gold-induced inhibition ofpeptide recogni-
tion may be due to the formation ofchelates
between Au(I) and cysteine thiol groups of
antigenic peptides. Such a process might con-
tribute to the therapeutic effects ofgold com-
pounds in RA. Griem et al. (110), Goebel et
al. (114), and Griem and Gleichmann (115)
have also observed that mononuclear phago-
cytes exposed to Au(I) in vitro are capable of
generating the reactive metabolite Au(III),
which could explain the various immune reac-
tions inducedbygold-containing compounds.
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Gold-Induced HumanAutoimmuity
RA patients treated with gold may develop
autoimmune responses to nuclear antigens
and platelets. A recent report has shown that
RA patients with gold-induced side effects
produce antinudear antibodies against the Ro
antigen (80). When the sera of 29 RA
patients positive for antinuclear antibodies
were tested by Western blot using recombi-
nant antigens (Ro 60 kD, Ro 52 kD, and La),
one group of 13 reacted only with Ro 52 kD,
another group of 10 reacted only with Ro 60
kD, and a third group reacted with all three
antigens. The first group had severe skin erup-
tions, the second group had either proteinuria
and/or leukopenia, and the third group had
Sjogren's syndrome (80). Thrombocytopenia
has also been observed in 1-3% ofpatients
treated with gold salts (81,116,117). An asso-
ciation with HLA-DR3 and the presence of
autoantibodies against platelet epitopes sug-
gest the importance ofimmunologic mecha-
nisms: platelet destruction may be mediated
by these autoantibodies, either acting alone or
in combination with gold (81,118).
Numerous reports ofgold therapyfollowed
by renal lesions can be found in the literature
of the 1960s and 1970s (85,119-121).
Proteinuria was detected in 6-17% and a
nephrotic syndrome in 2.6-5.3% of RA
patients treated with gold salts (86). The rela-
tive risk ofproteinuria during gold treatment
ofRA was increased 32 times in patients who
were HLA-DR3 positive (122-125). A survey
of 122 RA patients who underwent kidney
biopsy after the development ofproteinuria
showed that 41% ofthese subjects presented
with a nephrotic syndrome. Membranous
glomerulonephropathy was present in 89.5%
and minimal change nephropathy in 9.6%
(86,126,127). Such adverse effects ofgold
therapy are still occurring, as shown by a
recent report ofa patient affected by psoriatic
arthritis who after 3 years oforal gold therapy
developed membranous glomerulonephropa-
thy, autoantibodies to myeloperoxidase, and
vasculitis (128). It should be noted that there
are dose similarities between gold and penicil-
lamine nephropathy (127). Finally, in view of
the recent popularity offood supplements and
folk medicines, often imported from overseas
without a controlled designation oftheir com-
position, it is ofinterest that an oral tonic con-
taininggold (known as Gold Kushta) has been
associated with a nephrotic syndrome in some
subjects (101) and that lichenoid dermatitis
has been diagnosed in three patients who had
consumed an alcoholic beverage containing
gold (105).
AutoimmunityInducedbyGold
inExperimentalAnimals
Early studies performed in outbred Wistar rats
showed that injection ofsodium aurothiomalate
(0.025 mgonce aweek) causedproteinuriaafter
7 weeks oftreatment (129). Kidney histo-
pathology and immunohistopathology revealed
diffuse thickening ofglomerular capillary walls
as well as granular glomerular deposition ofrat
immunoglobulins and complement. Electron
microscopy showed electron-opaque deposits
along the epithelial aspect ofthe renal GBM
and loss ofepithelial foot processes. Gold was
detected only in proximal convoluted tubules.
Rabbits fed flour containing an indigenous
preparation ofgold oxide (Gold Kushta) or
injected with sodium aurothiomalate developed
proteinuria as well as thickening ofglomerular
basement membranes and electron-opaque
deposits (101). Similar effects followed the sub-
cutaneous administration ofsodium auroth-
iomalate to guinea pigs, with proteinuria, renal
lesions, and immune complex nephropathy
(130). Light microscopy revealed two different
histopathology patterns. The first, characterized
by interstitial mononuclear cell infiltration,
tubular destruction, and interstitial fibrosis, was
associated with the production ofautoantibod-
ies to tubularbasementmembranes. Thesecond
consisted ofthickening ofglomerular capillary
walls and mesangial cellularity. It was associated
with the production ofautoantibodies to renal
epithelial antigens and the glomerular deposi-
tion ofgranular immune complexes containing
renal antigens andtheirspecificautoantibodies.
These initial studies, performed in outbred
animals and lacking the more sophisticated
reagents and methods currently available, are
still ofsome value because they demonstrate
that different animal species are susceptible to
gold-induced autoimmune effects similar to
those experienced by humans. More recent
studies have provided additional details on the
pathogenesis of renal autoimmune disease
caused byexposure to gold. Inbred mice ofthe
A.SW strain (H-2S) treated with gold sodium
thiomalate produce autoantibodies to nucleo-
lar antigens (131,132). Because the immuno-
fluorescence pattern produced by these
autoantibodies is similar to that observed in
H-2S mice injected with mercury, it is likely
that the autoantigen involved is fibrillarin (see
"Mercury-Induced Renal Autoimmunity').
Mice ofthis strain develop elevated levels of
serum IgE, IgG, and IgM after 8 weeks ofgold
treatment (133). The oxidation state ofgold,
i.e.,Au(III) versusAu(I), seems to playa major
role in the immunotoxicity ofthis metal and
its induction ofautoimmune responses (132).
Brown Norway (BN) rats treatedwith gold
salts develop autoimmunity (83,84). Auto-
antibodies reacting with the renal GBM, and
in particular with laminin 1 (a component of
the extracellular matrix), were found in all ani-
mals injected with aurothiopropanolsulfanate
(84). Other autoantibodies (against nuclear
antigens, double-stranded DNA, thyroglobu-
lin, actin, myosin, and tubulin) were detected
in gold-treated BN rats. In addition, serum
IgE levels increased and showed a first peak at
the end ofthe firstweekofgold treatment and
a second, higher peak at the end ofthe third
week. After 4 weeks, intense linear IgG
deposits were present along the GBM and
tubular basement membrane (TBM). Indirect
immunofluorescence showed that eluates from
these deposits reacted in vitro with GBM and
TBM. Glomerular linear and/or granular
deposits were also observed after 8 weeks of
gold treatment. Light microscopy and electron
microscopy showed that kidneys were normal
after 4 weeks. Diffuse interstitial mononuclear
cell infiltrates and small electron-opaque
mesangial and subepithelial deposits were pre-
sent after 8 weeks in some rats. The authors
concluded that gold treatment of BN rats
results in an autoimmune membranous
glomerulopathy similar to that caused by mer-
curyandpenicillamine (84). The autoimmune
effects ofdifferent gold compounds, induding
some thiol-containing salts, were also exam-
ined in BN rats (83). Sulfur-containing groups
do not induce autoimmune responses but may
potentiate the autoimmune effects ofgold.
The BN rat model has been recently pursued
for studies ofthe cytokine network; both gold
and D-penicillamine were found to upregulate
the expression ofmRNAforratIL-4 (134).
Mercury-induced Renal
Autoimmunity
Mercury is a xenobiotic widely present in the
environment. Its levels are increasing as a
consequence ofthe processing of raw ores,
various industrial activities, and the discharge
ofmedical and scientific waste (44,98). One
of the major routes ofhuman exposure to
mercury may currently be the ingestion of
contaminated food, especially fish (135). The
potential health risks of mercury released
from dental amalgam fillings are still a source
ofcontroversy (74,136,137). Finally, a possi-
ble new source ofmercury exposure may be
unregulated dietary supplements and health
remedies that contain other metals such as sil-
ver and gold (101,138). Both inorganic and
organic forms ofmercury have immunotoxic
effects; suppression or potentiation ofcellular
immunity and antibody responses have been
observed in vitro and in vivo. There is also
solid evidence that mercury can induce
autoimmunity both in humans and experi-
mental animals (Table 2).
Effects ofMercuryonCells
ofthe ImmuneSystem
The various cellular components of the
immune system can be activated or inhibited
by low levels of mercury (Table 3) (44,
49,139-141). A monocyte-dependent inhibi-
tion ofphytohemagglutinin (PHA)- and phor-
bol-12-myristate-13-acetate (PMA)-induced
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proliferation and decreased production ofIL-2
has been observed in human T cells treated in
vitrowith HgCl2. In vivoexposure to mercury
increases T-lymphocyte responses in BALB/c
mice and decreases them in Swiss and (B6 x
C3)F, hybrid mice. Mercury also causes both
apoptosis and necrosis ofvarious T-cell lines
(142,143). Spleen cell cultures from HgCl2-
treated BN rats exhibit a marked decrease in
the concanavalin A-induced generation of
interferon (IFN)-y--producing cells, an inhibi-
tion likelycaused bynitricoxide (144,145).
Early studies showed that human B cells
treated with HgCl2 and pokeweed mitogen
were stimulated to produce IgE (150).
However, more recent investigations have
demonstrated that exposure to HgCl2 in vitro
may result in a dose-dependent inhibition of
human B-cell proliferation and immunoglobu-
lin yield (163). Similarly, murine B cells treated
in vitrowith mercuryexhibit inhibition ofboth
RNA and DNA synthesis and significant
decreases inproduction ofimmunoglobulin iso-
types (152). On the otherhand, B lymphocytes
from mercury-treated rats and mice are stimu-
lated to produce IgE and other immunoglobu-
lin isotypes (149,151,153,154). Investigations
of mercury effects on macrophages have
detectedinhibition ofphagocytosis andfreerad-
ical production. Depending on its in vitro con-
centration, HgCl2 stimulates H202 release from
Lewis (LEW) butnotBN macrophages andcan
inhibit phagocytosis in both LEWand BN resi-
dent peritoneal macrophages (155). Finally,
treatment with HgCI2 induces IL-1 production
by murine macrophages (156) and higher gene
expression ofIL-12 in spleen cells ofLEW rats
(164). Studies ofthe effects ofmercury on
human PMN are quite sparse. Concentrations
ofHgCl2 between 1 pM and 0.01 fM inhibited
adherence, polarization, chemotaxis, and ery-
throphagocytosis ofhuman PMN (157). In
addition, 1 nM to 1 fM HgCl2 significantly
stimulated H202 production and chemilumi-
nescence ofthese cells. Inhibition ofmicrobici-
dal activities and respiratory burst, decreased
superoxide anion formation, and chemotaxis
have also been detectedafterexposure tomethyl
mercury, mercuric chloride, and silver lactate
(158,165,166). Todate, therearefewinvestiga-
tions ofother types ofimmune cells. BN rat
peritoneal mast cells exposed to HgCl2 have
higher sensitivity to degranulation by a mono-
donal antibody to IgE (159). Finally, treatment
ofmice or rats with methyl mercury causes
reduction or suppression ofnatural killer cell
activity (141,162).
Mercury-Induced Human
Autoimmunity
At the present time mercury is not a frequent
cause ofhuman autoimmune disease. This
may be a consequence of its progressively
diminished use in medicine since mid-century,
following the introduction of powerful
nonmercurial diuretics and antiseptics. When
drugs containing mercury were commonly
used, they often caused autoimmune disease
(Table4).
Several instances ofmercury-associated
nephrotic syndrome after treatment with
organomercurial diuretics for congestive heart
failure, ingestion ofmercury-containing laxa-
tives, or the protracted use ofammoniated
mercury in skin ointments for the treatment
ofpsoriasis have been reported in the litera-
ture (86). A nephrotic syndrome associated
with the use ofskin-lightening creams con-
taining mercury was also observed in numer-
ous East African patients (87,89). Direct
immunofluorescence showed that IgG and
complement were bound at the level ofthe
renal GBM in kidney biopsies from these
patients. The nephrotic syndrome resulting
from treatment with mercury was due to
renal histopathologic lesions defined as mem-
branous glomerulonephritis, membranous
nephropathy, or membranous glomerulo-
nephropathy (15-17). The lack ofinflamma-
tory changes at the glomerular level suggests
that the two latter terms may be more appro-
priate. As noted in a recent textbook ofgen-
eral pathology, "the suffix -itis usually means
inflammation ofthat organ or tissue (appen-
dic-itis, mening-itis, pleur-itis)" (168). The
presence ofglomerular immune deposits can-
not be considered equivalent to an ongoing
inflammatory process, as antibody-mediated
damage may occur without the presence of
neutrophils, lymphocytes, and/or macro-
phages in the target tissues (29,169,170).
Occupational exposure to mercury does
not usually result in autoimmune responses
and disease (58,59). Early reports that work-
ers in mercury-producing industry developed
circulating antilaminin antibodies have not
been confirmed (58,171-173). However, one
cohort ofworkers exposed to mercury had a
slight increase in autoantibodies to DNA
(58). This observation may be ofsome inter-
est, a few subjects with industrial exposure to
mercuryhave also developed antinuclear anti-
bodies, sclerodermalike disease, lichen planus,
or membranous nephropathy (91,92,167).
Thus, when one examines the relevant
literature, it is evident that mercury can cause
autoimmune responses and disease in humans
(Table 4), even ifchanges in therapeutics have
obviously led to a decrease ofthese effects.
However, the risk ofautoimmune conse-
quences continues to be present because mer-
cury is currently used as a preservative in some
immunoglobulin andvaccinepreparations, and
may be a contaminant offish (135), imported
food supplements, and unregulated health
remedies. An additional but still controversial
sourceofverylowlevels ofmercuryis provided
bydental amalgam (74,136,137,174). Clearly,
it is quite difficult to study in human subjects
the autoimmune effects ofthe chronic expo-
sure to very low levels ofmercury, either alone
or in association with other xenobiotics. These
difficulties are not encountered when using
experimentally inducedmodels ofautoimmune
disease that provide the opportunity (otherwise
impossible in clinical investigations) to initiate
the exposure oflaboratory animals to different
doses ofxenobiotics and ascertain their patho-
genetic potential. Such investigations have pro-
vided excellent evidence that administration of
mercury causes autoimmunity in rabbits, rats,
and mice.
Mercury-InducedAutoim* unity in
NewZealandWhiteRabbits
Mercury treatment ofoutbred New Zealand
White (NZW) rabbits resulted in the forma-
tion ofimmune deposits in kidneys and other
Table 3. Effects of mercury on the immune system.
Cells ofthe immune system Effects of mercury References
T lymphocytes 1 4, (1 or41 IFN-y' IL-4) (144,146-148)
B lymphocytes T 1 (149-154)
Macrophages I4 1(phagocytosis, free radicals, IL-1) (141,155,156)
Polymorphonuclear leukocytes 1 1(chemotaxis, phagocytosis, free radicals) (157,158)
Mastcells T 4, (degranulation, IL-8,TNF-a, IL-4) (159,160)
Natural killercells 1(killeractivity) (161,162)
Othercells ? (44)
Abbreviations: T, increase; -1, decrease; ?, unknown; IFN, interferon; IL, interleukin; TNF, tumor necrosisfactor.
Table 4. Mercury-induced human autoimmunity.
Source of mercury Autoimmune responses
exposure and immunopathology Autoimmune disease References
Diuretics Immune deposits in renal GBM Nephrotic syndrome (86)
Laxatives Linear and/orgranularlgG and C3 atGBM Nephroticsyndrome (86)
Skin ointments Linear and/orgranular lgG and C3 at GBM Nephrotic syndrome (87-89)
Occupational Autoantibodies to laminin 1 (?), ANA, Autoimmune kidney (58,90-92,167)
oraccidental autoantibodies to DNA disease, lichen planus,
Linearand/orgranular lgG and C3 at GBM sclerodermalike disease
Abbreviations: ?, reported, but notconfirmed;ANA, antinuclearantibodies; GBM, glomerular basement membrane.
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organs with two-stage kinetics (Table 5)
(175). In the firststage, linear deposits ofrab-
bit IgG (but not C3) were present in renal
GBM and TBM. The immunoglobulins
eluted from these deposits reacted with still
unidentified autoantigens ofthe extracellular
matrix. At this time, the histology ofthe kid-
ney did not show abnormalities and there was
only slight proteinuria. The second stage was
observed after 5-7 weeks ofHgCI2 treatment
and was characterized by granular deposits of
IgG and C3 in GBM and TBM. Immuno-
globulins eluted from these deposits reacted
with components ofthe extracellular matrix.
In this stage, light microscopy revealed thick-
ening of the glomerular capillary walls in
60% of the rabbits. Electron microscopy
identified focal electron-opaque subepithelial
deposits. In summary, outbred rabbits
injected with mercury experienced autoim-
mune responses to epitopes ofthe extracellu-
lar matrix. The kidney glomerulus was the
major target, with in situ formation of
immune complexes that caused morphologic
and functional damage suggestive ofa mem-
branous nephropathy.
It is unfortunate that this model has
not been used for additional in-depth investi-
gations of the autoantigens involved.
Dose-response studies would also be useful.
Nonetheless, the available evidence demon-
strates that a certain percentage ofoutbred
animals are susceptible to the autoimmune
effects ofmercury and may actually develop
an immune complex-mediated nephrotic syn-
drome after exposure to this metal.
MouseModels ofMercury-Induced
Autoi*munity
The mouse, currently the preferred animal for
immunology studies, has been very useful in
the investigation of mercury-induced
autoimmunity (Table 6). Mice ofvarious
inbred strains (A/J, A.SW, B1O.S and SJL/J)
or outbred ICR mice treated with HgCl2
develop antinucleolar and antinuclear autoan-
tibodies (49,176,178-180,182-185). The
antinucleolar autoantibodies react with fibril-
larin (U3 RNP protein) and occasionallywith
other nucleolar proteins of60-70 and 10-15
kDa. This reaction is similar to that observed
with autoantibodies from a subset ofpatients
with scleroderma (180,186). Autoantibodies
to fibrillarin belong to all IgG subclasses, with
a predominance ofIgGI and IgG2a isotypes.
They are detected after 3-5 weeks ofmercury
treatment and can be found in the circulation
for 10-12 weeks and up to at least 1 year
after discontinuation ofmercury treatment.
Dose-response studies have shown that
autoantibodies to fibrillarin develop in mice
treated with at least 1.225 ppm HgCl2 in
their drinking water for 10 weeks, a dose
resulting in a mercury body burden similar to
that observed in some occupationally exposed
human subjects (183). A smaller percentage
ofmercury-treated mice produce autoanti-
bodies to epitopes ofnuclear antigens (chro-
matin and/or histones). The autoimmune
effects of mercury in mice are in large part
determined by the MHC, but background
non-MHC genes may also be involved, as
occurs in rats (187,188).
The kidneys ofmercury-treated inbred
(SJL, ASW, BALB/c) and outbred ICR mice
contain granular immune deposits, mostly
localized in the glomerular mesangium and
the walls ofinterlobular arterioles and arteries
(178). Interestingly, mice ofthe A.CA/SnJ,
DBA/lJ, and P/J strains that also produce
antifibrillarin autoantibodies do not show
renal immune deposits, for reasons that are
Table 5. Kidney autoimmunity induced by HgCI2 in NewZealand White rabbits.
Stage Autoimmune responses Kidney immunopathology Kidney histopathology Reference
First stage (2-3 Autoantibodies to Linear deposits of IgG and Normal appearance of (175)
weeks of HgCI2 extracellular matrix C3 in GBM and TBM GBM and TBM
injections) (laminin 1 ?)
Second stage Autoantibodies to Granular deposits oflgG Subepithelial immune (175)
(5-7 weeks of extracellular matrix and C3 in GBM and TBM deposits (membranous
HgCI2 injections) (laminin 1 ?) nephropathy after 8-12
weeks)
Abbreviations: ?, still unidentified; GBM, glomerular basement membrane; TBM, tubular basement membrane.
Table 6. Mouse models of kidney autoimmunity induced by HgCI2.
Inbred Kidney immuno- Kidney Duration of
strain Autoimmune responses pathology histopathology autoimmunity References
SJL/J Autoantibodies to Granular deposits of Mesangial At least 1 year (131,
A/J fibrillarin (and auto- lgG and C3 in glomerulopathy 176-180)
A.SW antibodies to histones) renal mesangium
B1O.S
A.CA/SnJ, Autoantibodies to None detected None detected Not reported (181)
DBA/1J, fibrillarin (and auto-
P/J antibodies to histones)
still unclear (181). Immune deposits present
in kidneys ofSJL mice comprise IgG (con-
taining autoantibodies to fibrillarin) and C3.
Kidneyhistopathology is minimal and does
not show serious inflammatory damage. It is
characterized by widening ofglomerular
mesangial areas, electron-opaque deposits,
and a moderate increase ofendocapillary
cells. The preferential involvement of the
mesangium suggests the term mesangial
glomerulonephropathy. In conclusion, the
pathogenesis ofmercury-induced kidney
autoimmune disease in mice may be due to
deposition ofimmune complexes and activa-
tion of the complement system. The lack of
detectable inflammatory cells raises doubts
about a pathogenetic role of effector
neutrophils,lymphocytes, andmacrophages.
RatModels ofMerurya-Induced
Autoimm t
The first rat model for immunopathologic
investigations ofautoimmunity caused by
mercury was established in outbred Wistar
rats injected subcutaneously three times a
weekwithHgC12 (189).Approximately 33%
ofthese rats developed significant proteinuria
and a membranous glomerulonephropathy,
with diffuse thickening ofglomerular capil-
lary walls and granular subepithelial deposits
ofimmunoglobulins and complement. A
similar model, but with a much higher inci-
dence ofautoimmunity, was later developed
in inbred rats (190,191). Up to 100% of
mercury-treated BN, MAXX, and Dorus
Zadel Black (DZB) rats produce autoanti-
bodies toantigens ofthe renal GBM, inparti-
cular laminin 1 (Table 7). The concentration
ofthese autoantibodies in the serum increases
9-10 days after the start of mercury treat-
ment and usually reaches a peak after 14-15
days. Circulating autoantibodies to laminin 1
decrease after 16-18 days and eventually
return to baseline levels in thefollowingdays.
The isotypes ofthese autoantibodies are usu-
allyIgGI and IgG2a (201,202). As shown in
Figure 1, IgGI and IgG2a autoantibodies to
laminin 1 increase significantly on day 11 of
mercury treatment, but only those of the
IgGI isotype are still significantly elevated on
day 15. Interestingly, binding of rat comple-
ment by these autoantibodies has not been
detected either in vivo or in vitro (192,203).
After BN rats have recovered from mercury-
induced autoimmunity, they no longer
develop autoimmune responses following fur-
ther treatment with this metal. Serum
autoantibodies against laminin 1 are also pres-
ent in untreated BB rats with insulin-depen-
dent diabetes mellitus and exposure to mer-
cury increases both autoantibody levels and
percentage of rats with circulating laminin
antibodies (197). Rats of the PVG strain
develop autoantibodies to nuclear antigens
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Table 7. Rat models of kidney autoimmunity induced by HgCI2.
Rat Duration of
strain Autoimmune responses Kidney immunopathology Kidney histopathology autoimmunity References
Outbred Not reported Linear/granular deposits of lgG in Membranous glomerulo- Not reported (189)
Wistar GBM andTBM nephropathy
Inbred BN Autoantibodies to laminin 1 (autoantibodies Linear/granular deposits of IgG in Membranous glomerulo- 30 days (190-193)
and MAXX tothyroglobulin, myeloperoxidase, DNA) GBM and TBM nephropathy
Inbred DZB Autoantibodies to laminin 1 Faint linear and strong granular deposits Membranous glomerulo- Not reported (194)
of lgG and C3 in GBM and TBM nephropathy
Inbred PVG Antinuclearantibodies (antihistones) Granular deposits of lgG and C3 in Membranous glomerulo- Not reported (195,196)
GBM and TBM nephropathy
Inbred BB(DP) Autoantibodies to laminin 1, thyroglobulin No IgG deposits None induced by HgCI2 Not reported (197)
Inbred LEW Suppression No IgG deposits None induced by HgCI2 Not reported (198-200)
Abbreviations: BN, Brown Norway; DP, diabetes prone; DZB, Dorus Zadel black; GBM, glomerular basement membrane; LEW, lewis rats; TBM, tubular basement membrane.
after mercurytreatment. To date no antibodies
to laminin 1 orother autoantibodies have been
detected in these animals. Finally, rats from
the LEW and several other inbred strains are
resistant to the autoimmune effects ofmercury
(191,204).
Autoantibodies to DNA, thyroglobulin,
type IV collagen, heparan sulfate proteogly-
can, entactin, etc., have also been detected in
BN rats after exposure to mercury. However,
they are usually present at low levels for brief
periods oftime and do not seem to cause dis-
ease ofthe kidney, thyroid, or other organs.
Conversely, mercury-treated BN, MAXX,
and DZB rats have renal immune deposits
containing autoantibodies to laminin 1. The
kinetics ofimmune complex deposition are
similar to those observed in HgCl2-injected
outbred rabbits but with an accelerated
course. The first stage, identified by linear
deposits ofIgG (mostly IgGI and IgG2a) in
GBM and TBM, reaches a maximum on
approximately the 15th day of treatment.
Eluates from these deposits contain autoanti-
bodies to laminin 1, whereas C3 is usually
undetectable. Linear deposits ofIgG (likely
containing the same autoantibodies) are pre-
sent in basement membranes ofspleen, liver,
adrenals, and heart (44,205). Similar linear
deposits ofIgG are also found in basement
membranes ofthe intestine after oral admin-
istration or subcutaneous injection ofHgCl2
(44,206). The second stage ofimmunedepo-
sition is observed after 15-20 days ofmercury
treatment and is characterized by granular
IgG at the level of renal GBM and TBM.
Autoantibodies to laminin 1 are also detected
in eluates from these deposits. The renal
immunopathology ofHgCl2-injected DZB
rats is slightly different because after 6-10
days of treatment there is only a faint linear
IgG deposition along the GBM. Abundant
granular IgG deposits become evident at a
later time. Mercury-treated PVG rats experi-
ence onlygranular IgG deposits in the GBM,
without an initial linear stage. It is also of
interest that HgC12-injected BB rats with cir-
culating autoantibodies to laminin 1 have no
immunoglobulin deposits either in the GBM
or other tissues.
The clinical signs induced by mercury
in BN and MAXX rats are reminiscent of
the human nephrotic syndrome. Peak levels
of proteinuria are usually detected after
14-16 days ofmercury treatment, with high
levels still present after 32 days (192).
Autoantibodies against laminin 1, present in
the circulation of mercury-treated BN,
MAXX, and DZB rats, may have a patho-
genic role, as demonstrated by their correla-
tion with proteinuria. The proteinuria
observed in BN and MAXX rats with autoan-
tibodies to laminin 1 but no C3 in renal
immune deposits likely is a direct conse-
quence ofautoantibody binding to the GBM.
Antibodies alone, in the absence ofcomple-
ment, neutrophils, or other known secondary
mediators, can cause glomerular injury and
proteinuria (29). An alternative cause ofpro-
teinuria in DZB and PVG rats with renal
immune deposits containing complement
components is the activation ofthe classical
complement pathway.
The histopathology ofthe renal damage
caused by mercury-induced autoimmunity in
BN, MAXX, and DZB rats is characterized by
rather minor changes. An early publication
reported various numbers of large mono-
nuclear cells in glomeruli and focal detach-
ment ofglomerular endothelial cells as well as
subendothelial and scattered subepithelial
deposits (207). In our experiments with BN
rats, the most prominent and frequent lesion
was the detachment ofendothelial cells from
the GBM (208). Electron-opaque material,
loose to compact floccular, was often present
in the spaces created by the uplifting ofthe
endothelial cells. These changes were observed
in kidneys obtained on day 15 and day 30 of
mercury treatment but were more pro-
nounced in the latter. Occasionally, there was
mesangial expansion ofperipheral capillary
loops with resulting splitting. Rare capillary
loops showed small subepithelial electron-
opaque deposits. To obtain more precise mor-
phologic information, we examined kidneys
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Figure 1. Mercury treatment induces the production of
IgGl and IgG2a autoantibodies to laminin 1, as
detected by ELISA on day 11. The increase in serum
autoantibody levels is negatively correlated with the
decrease in the percent of RT6.2+ T lymphocytes in
peripheral lymph nodes.
from mercury-treated MAXX rats after in vivo
perfusion with glutaraldehyde (192).
Depending on the length of treatment, we
observed two different histopathologic pat-
terns. Kidneys obtained on the ninth day of
mercury administration showed mild
glomerular alterations, againwith focal separa-
tion ofendothelial cells from the GBM. No
electron-opaque deposits were observed at that
time. Kidneys obtained on day 32 showed
increased separation ofendothelial cells from
the GBM with accumulation offlocculent
electron-opaque material between the
endothelial cells and the GBM. Some capillary
loops showed thickening and splitting ofthe
GBM with expansion ofthe mesangium. On
both day 9 and day 32, visceral epithelial cells
showed swelling ofcell processes and focal
foot process fusion. There were no subepithe-
lial deposits or significant influx ofinflamma-
tory cells in the glomeruli. In conclusion,
initial observations in mercury-injected BN
rats may have led to the definition of the
histopathology as a glomerulonephritis.
However, as previously discussed for renal
lesions induced in humans by mercury, the
term may not be appropriate because ofthe
lack of a strong inflammatory component.
Better definitions may be membranous
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glomerulonephropathy or membranous
nephropathy.
Splenomegaly, lymph node hyperplasia,
and thymic atrophy are detected in HgC12-
treated BN rats. Extensive disorganization
of the thymus, with loss of demarcation
between cortex and medulla but without any
detectable increase in apoptotic cells, occurs
within 14 days of treatment (209). The
numbers ofthymus cells and the percentage
of CD8+CD4+ double-positive thymocytes
decreases, whereas the percentage ofsingle-
positive CD8+ or CD4+ and double-negative
CD8-CD4- thymocytes increases (209).
Total numbers ofdouble-positive CD8+CD4+
thymocytes decrease, but total numbers of
CD4+ single-positive thymocytes increase.
We have also observed that HgC12-treated
BN rats have a decrease of RT6+ T cells
(202,210). Kinetic studies of this change
have shown significant percentage decreases
after 8, 11, and 15 days ofHgCl2 treatment
and an inverse correlation with autoimmune
responses to laminin 1 (Figure 1). Two-color
flow cytometry has revealed that percentages
of both RT6.2+CD4+ and RT6.2+CD8+
T lymphocytes decrease on day 15 ofmercury
treatment (202). Studies ofdiabetes-prone
BB rats have suggested that RT6+ T cells may
have a still unexplained immunoregulatory
role (211-214).
As previously mentioned, the histo-
pathology observed by most investigators of
this rat model is a membranous glomeru-
lonephropathy without evident lesions in
other tissues. More recently, inflammatory
processes in various organs and tissues of
mercury-treated BN rats have been reported.
Inflammation and ulceration of the skin,
hepatic periportal mononuclear cell infil-
trates, and hemorrhagic lesions of the gut
with intense submucosa inflammation and
leucocytoclastic vasculitis have been observed
(215-219). These rats produce antibodies to
myeloperoxidase and develop a CD8+
T-lymphocyte-mediated inflammatory
polyarthritis. A focal inflammatory process of
the parotid, submandibular, and lachrymal
glands similar to the lesions ofSjogren's syn-
drome has also been detected in HgC12-
treated BN rats (220,221). Because we had
never observed any of these lesions, we
recently re-examined a variety oftissues from
various groups ofBN rats injected with mer-
cury. In spite ofavery careful examination of
plastic-embedded toluidine blue-stained sec-
tions as well as paraffin-embedded H&E-
stained sections, we have not been able to
detect inflammatory changes in thyroid, pan-
creas, intestine, skin, liver, parotid, and lung
(44). At present, we cannot explain the dif-
ference in histopathology between our BN
rats and those examined by other investiga-
tors. However, it has been reported that the
inflammatory changes observed in various
tissues disappear after antibiotic treatment,
which suggests possible synergistic effects of
mercury and microorganisms in rats that are
not specific pathogen-free (218).
Cytokine profiles obtained using quantita-
tive and semiquantitative PCR have suggested
the hypothesis that an imbalance between T-
helper (Th)1 and Th2 cells might be the basis
ofmercury-induced autoimmunity (45,46).
Another approach to assess the in vivo func-
tional effects ofcytokines relies on the determi-
nation of immunoglobulin isotypes of
autoantibodies. Autoantibodies to laminin 1
detected in HgCl2-treated BN rats are ofthe
IgGI and IgG2a isotypes, confirming the sug-
gestion of a polarized, type 2 cytokine profile
in these animals (193,201,202). In contrast,
after exposure to mercury, BB rats develop
autoantibodies to laminin 1 ofall IgG isotypes,
including those likely dependent on Type 1
cytokines (202). These findings indicate that
the type ofcytokine production induced by
mercury treatment may vary because ofdiffer-
ent immunogenetic and/or pharmacogenetic
characteristics ofeach rat strain. Both MHC
and non-MHC genes are important in
autoimmune responses to mercury. BN and
MAXX rats (RT-1nhaplotype) have autoim-
mune responses to laminin 1 after mercury
administration (192,222). Most other inbred
rat strains, with the LEW (RT-11 haplotype) as
the prototype, are resistant to these autoim-
mune effects (222). Particularly relevant in this
regard are the findings in mercury-treated
BN.1L and LEW.IN rats (i.e., animals that
are congenic between the responder BN and
the resistant LEW). None ofthese rats exhibit
autoimmune responses to laminin, renal
immune deposits, or proteinuria (204,223).
On the other hand, circulating autoantibodies
to laminin and IgG deposits in renal GBM can
be induced by exposure to mercury in
BN-*LEW.1N chimeras (223). This demon-
strates that both MHC and non-MHC back-
ground genes must be present for the
induction ofautoimmunity bymercury.
Finally, an interesting aspect ofmercury
immunotoxicity are the suppressive effects of
this metal on autoimmune disease experimen-
tally induced in LEW rats. Mercury inhibits
experimental Heymann's nephritis, autoim-
mune encephalomyelitis, and autoimmune
uveitis in LEW rats. This suppression may
occur through the stimulation ofnon-antigen-
specific CD8+ "suppressor/cytotoxic cells" T
lymphocytes (199), a lack ofbalance between
Thl and Th2 cytokines (47), or the secretion
oftransforming growthfactor-,B byautoreactive
anti-class II CD4+ T cells (224). We have
recently demonstrated that mercury had no
inhibitory effects on the spontaneous develop-
ment andprogressionofinsulin-dependent dia-
betes mellitus and thyroiditis in diabetes-prone
BB rats (197), which suggests that the
immunosuppressive effects ofHgCl2 may be a
characteristicunique to theLEWstrain.
Conclusions
The clinical observations and animal
experiments summarized in this review allow
some considerations about renal autoimmu-
nity associated with metals. There is no doubt
that exposure to gold and mercury can cause
autoimmune responses in humans. A clear-cut
correlation between administration ofthese
metals and development of autoimmune
responses has also been established by studies
ofexperimental animals. In general, metal-
induced autoimmune responses can either be
harmless or result in autoimmune disease,
depending on variables that are still unclear.
The role ofgenetic factors is obviously very
important in mouse and rat models ofmetal-
inducedautoimmunity. However, we still lack
a precise definition ofthe immunogenetic,
pharmacogenetic (ecogenetic), or othergeneti-
cally determined conditions involved in the
development ofhuman autoimmunity caused
by metals. Even the animal models have unex-
plained aspects. The administration ofsilver
compounds to inbred mice induces the pro-
duction ofautoantibodies to fibrillarin that
for unknown reasons do not cause thedeposi-
tion ofimmune complexes in the kidney or
result in other tissue damage. In contrast,
autoantibodies induced by gold and mercury
can form immune complexes in the kidney
and cause renal pathology. The role of
inflammatory cytokines and/or cytotoxic
T cells in animals and humans exposed to
metals is also unclear(225,226).
Xenobiotic-induced autoimmunity often
differs fromidiopathic orspontaneously occur-
ring autoimmunity, as demonstrated by the
toxic oil syndrome and the eosinophilia-myal-
gia syndrome. These disorders were character-
izedby avarietyofautoimmune responses, but
their dinical manifestations differed from idio-
pathic autoimmune disease (227). There are
also notable clinical and laboratory discrepan-
cies between drug-related lupus and SLE
(227,228). On the contrary, autoimmune
diseases induced bypenicillamine (SLE, pem-
phigus, myasthenia gravis) are identical or
quite similar to the corresponding idiopathic
disorders (42). Gold- and mercury-induced
renal disease has a pathology comparable to
membranous glomerulonephropathy due to
other causes or ofidiopathic nature. We still
do not know the autoantigens involved in
autoimmune responses induced in humansby
these metals, but mouse and rat models sug-
gest that they may be laminin 1, fibrillarin,
and nuclear histones.
It should also be stressed that animal
models ofmetal-induced autoimmunity are
not exactlycomparable to human disease. The
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systemic autoimmune responses induced by
gold and mercury in rabbits, rats, and mice are
different from those ofhuman SLE. As men-
tioned above, BN rats treated with mercury
produce autoantibodies to laminin 1. There is a
good correlation between levels of these
autoantibodies and proteinuria. Other autoan-
tibodies (including anti-DNA antibodies) that
have been detected in these rats are not associ-
ated with functional or morphologic kidney
damage. In addition, the specificity ofanti-
DNA antibodies present in mercury-injected
BN rats may be questionable, as polyreactive
antibodies havebeen identified in someanimals
(229). Mercury-treated SJL mice produce
autoantibodies to a nucleolar antigen, fibril-
larin, similarly to some patients with sclero-
derma. SLE patients make autoantibodies to a
variety ofautoantigens but do not usually
develop clinically relevant levels ofantifibril-
larin or antilaminin antibodies. The most likely
pathogenic autoantibodies in SLE patients are
directed against epitopes ofdouble-stranded
DNA and various ribosomal antigens
(186,230-232). Thus, mercury does not seem
to induce an SLE-like syndrome in rats or
mice. The xenobiotic-induced animal model
that most resembles SLE may very well be the
autoimmune diseasecaused bypristane in some
inbred strains ofmice. SJL/J mice treated with
this xenobiotic develop autoantibodies to ribo-
somal P antigens (a lupus-related specificity)
and immune complex glomerulonephritis
(233). Pristane-treated BALB/c mice develop
rheumatoid factor-positive erosive arthritis and
a lupuslike syndrome characterized by immune
complex-mediated glomerulonephritis and cir-
culating autoantibodies to nRNP/Sm, Su, and
single-stranded DNA (233).
As mentioned at the beginning ofthis
review, SLE ischaracterizedbyawidespectrum
ofrenal pathologic changes, from mesangial
and membranous nephropathy to severe
glomerulonephritis, often leading to sclerosing
nephropathy (23,234,235). Renal manifesta-
tions in patients with systemic sclerosis are
caused by arterial and glomerular lesions, with
fibrinoid necrosis and fibrotic changes (236).
In contrast, the renal histopathology observed
in rat models ofmercury autoimmunity shows
scarce alterations ofkidney structures, lacks
major inflammatory reactions, and is usually
defined as a membranous nephropathy, not a
glomerulonephritis (201). Similarly, both
immunohistopathology and histopathology of
mercury-induced autoimmunity in SJL mice
reveal immune deposits at the mesangial level,
expanded glomerular mesangial zones with
electron-opaque deposits, and a moderate
increase ofendocapillary cells (178,188). The
absence ofinflammatory or other major struc-
turalchanges suggests thatthis pathology is best
described by the term mesangial glomeru-
lonephropathy.
In both rats and mice, mercury treatment
causes a nephrotic syndrome, i.e., abundant
proteinuria. BN, MAXX, and DZB rats pro-
duce autoantibodies against laminin 1, a
component ofthe renal GBM. These auto-
antibodies likely have a pathogenetic role and
may cause proteinuria through direct autoan-
tibody effects or activation of the comple-
ment cascade. PVG rats and SJL mice treated
with mercury may develop proteinuria
because of renal immune deposits containing
autoantibodies to nuclear and nucleolar anti-
gens plus complement components. As
previously mentioned, both cytotoxic T lym-
phocytes and cytokine-producing T lympho-
cytes and macrophages may cause additional
damage, but to date there is no solid evidence
in favor ofsuch effects.
Autoimmune responses and renal disease
caused in humans by gold and mercury usu-
ally end after withdrawal of the metal.
Animal models differ depending on the
species. Mercury-induced autoimmunity in
BN and MAXX rats develops rapidly and
spontaneously terminates within a month
even if the administration of the metal is
continued. Instead, mice need a much longer
time ofexposure to mercury for the develop-
ment ofautoimmune responses but continue
producing autoantibodies to fibrillarin for
up to 12 months after mercury treatment
is interrupted.
The issue of facilitation versus de novo
induction ofautoimmunity often arises and
has no easy answer. A relatively short period
ofexposure to a metal maysuggest facilitation
ofan underlying disease. De novo induction
ofautoimmunity may be implied by a longer
period. Lithium seems to facilitate auto-
immunity in individuals that have either low-
grade or initial thyroid disease. Mercury may
both facilitate and induce autoimmunity
de novo. The administration of HgC12 to
(NZB x NZW)F1 mice, susceptible to
murine lupus, stimulates a polyclonal B-cell
activation, with high levels of IgGI, IgG3,
and IgE immunoglobulins, and intense
autoantibody production against double-
stranded DNA, IgG, and collagen (153).
Similarly, mercury treatment facilitates
autoimmune responses to thyroglobulin and
laminin 1 in BB rats, susceptible to develop
insulin-dependent diabetes mellitus and thy-
roiditis (197). In addition, gold and mercury
can induce autoimmunity de novo in outbred
rabbits and guinea pigs as well as inbred rat
and mouse strains that do not spontaneously
develop autoimmune responses and disease.
Another issue of particular interest and
difficult solution is the role of certain struc-
ture-activity relationships in gold- and mer-
cury-induced autoimmunity. A possible role
ofthe interaction with thiols was initially sug-
gested by studies with penicillamine and gold
compounds. Gold, mercury, and silver have
high affinities for thiol groups and the forma-
tion ofdisulfide bonds between -SH groups
and thiols ofself-proteins might alter the
structure of autoantigens or reveal hidden
epitopes. Changes in fibrillarin epitopes
caused by mercury treatment have been
recently demonstrated (237). In addition,
metals might form disulfide bonds with cell
surface structures and activate immune cells.
Unfortunately, this issue is complicated by
other metals such as lead, copper, and cad-
mium that have affinity for thiol groups but
do not usually induce autoimmune responses.
The limited percentage ofhuman subjects
developing autoimmunity after exposure to
gold or mercury has a parallel in early experi-
mental studies showing that relatively small
percentages ofoutbred animals exhibited
autoimmunity after treatment with these
metals. The genetic makeup ofhuman popu-
lations is usually quite diverse; therefore, it is
not surprising that renal autoimmunity
induced by metals is not a common occur-
rence (173). More recent laboratory investi-
gations have discovered that gold and
mercury cause autoimmunity only in a few
strains of inbred mice and rats. The pene-
trance of mercury- and gold-induced auto-
immune disease in these susceptible inbred
strains reaches 100%. Most other inbred
strains are completely resistant to the auto-
immune effects ofmercury and gold. These
observations have suggested that immuno-
genetic and pharmacogenetic (ecogenetic)
factors are necessary for the expression of
autoimmune disease induced by mercury and
other metals (39,43,44). Ifsuch susceptible
genotypes exist in humans, only a small per-
centage ofmetal-exposed individuals is likely
to develop autoimmune disease.
As previously mentioned, it is difficult to
evaluate whether human autoimmunity is
caused by an environmental metal, especially
when multiple xenobiotics are involved, the
initial exposure did not occur in the work-
place, or the exposure happened in the distant
past. In this respect great help is provided by
the various animal models, as researchers
know the metal involved as well as the initial
time and dose of exposure. However, the
molecular, biochemical, and cellular events
involved in the induction ofmetal-induced
autoimmunity are still unclear. Gold and
mercury may cause autoimmune responses by
their effects that can stimulate the immune
system following indirect or direct pathways
(Table 8) (39,44,48,110). We have previ-
ously mentioned that these metals, acting on
tissues and organs ofthe body, may modify
autoantigen structure and expose new or
cryptic epitopes. A good example is provided
by the interaction of mercury with the
autoantigen fibrillarin, changing its molecular
Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999 761P.E. BIGAZZI
Table 8. Summary ofgold and mercury effects that may lead to autoimmunity.
Indirect pathway Direct pathway
Modification ofautoantigen structure (exposing Activity as immunogen
new orcryptic epitopes)
Release of nuclearautoantigens Mitogenic effects on T cells
Release of nucleolar autoantigens Sequential activation ofT-helper lymphocytes (Th2 >
Thl ?; other?)
Release of cytoplasmic autoantigens Stimulation of B lymphocytes
Release of extracellular matrix components Activation of macrophages and other antigen-presenting
cells
Upregulation of stress proteins (?) Upregulation of costimulatory pathways and adhesion
molecules
Molecular mimicry between epitopes of metal and Inhibition of immunoregulatory cells (?)
host autoantigens (?)
Abbreviations: ?, needs additional evidence; Th, T helper.
and antigenic properties. Mercury can also
induce the expression ofheat shock proteins
(stress proteins) and/or release cellular or
extracellular matrix components. Gold and
mercury can directly activate the immune sys-
tem by stimulating immune cells or acting as
immunogens or haptens. They may affect Th
cells, regulatory T lymphocytes, and B lym-
phocytes, and upregulate costimulatory path-
ways and adhesion molecules. Finally, metals
may favor epitope presentation by macro-
phages and other antigen-presenting cells and
stimulate their cytokine production. Changes
in the cytokine network and loss ofimmune
tolerance to autoantigens are likely conse-
quences ofthese interactions between heavy
metals and cells of the immune system.
Increased levels ofIgE and IgGI in mercury-
treated rats and mice as well as initial results
using antibodies to IL-4 suggested that this
cytokine might be an important mediator of
T-cell-dependent B-cell activation (148). In
this view, mercury would cause a lack ofbal-
ance between Thl and Th2 cells (45,46,
93,238). However, recent experiments in
cytokine-knockout mice treated with mercury
have not confirmed this hypothesis and have
shown that IL-4 is not required, whereas
IFN-y is essential for the production of
autoantibodies to fibrillarin (239). IFN-y
may be necessary to stimulate immune
responses to self-antigens, possibly through
the increase in MHC class II and class I
expression (facilitating epitope presentation)
and/or the induction ofcostimulatory factors.
Once autoimmunity is initiated, it may even-
tually develop in type 2 and/or type 1
cytokine-regulated responses, depending on
cytokine level and balance, costimulatory
molecules, autoantigen structure, and con-
centration and other environmental factors.
In conclusion, a single mechanism is
unlikely to be responsible for the induction of
autoimmune responses and disease by metals.
Studies ofthese complex events are obviously
difficult and may only be helped by in-depth
investigations of animal models, that allow
better control ofsome variables involved in
the autoimmune process. Because of its
diverse immunotoxic properties, mercury
should be considered a paradigm of metal-
induced autoimmunity (44). In vitro and in
vivo research ofautoimmune disease caused
by mercury, gold, and other metals has
already yielded extremely valuable informa-
tion and answered a number of important
questions. At the same time it has raised vari-
ous issues about possible immunostimulatory
or immunosuppressive mechanisms ofxeno-
biotic activity. Thus it is evident that investi-
gations ofmetal-induced autoimmunity have
the potential to produce new knowledge with
relevance both to autoimmune disease caused
by xenobiotics in general and to idiopathic
autoimmunity.
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